RANI
Rani Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.88 / 10
Netural
Analyst sentiment is mixed: one Strong Buy from HC Wainwright, yet historical win‑rate is 0% and market expectation is pessimistic with a 38.6% price drop. Conversely, fund‑flow score is 7.77/10, showing strong, positive inflows across all size categories.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-27
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate0.0%
What is the analyst consensus for RANI?
- RANI holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.88/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
